Could a simple cream reduce the need for major mole removal surgery?
NCT ID NCT04999631
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether a topical cream called squaric acid dibutyl ester (SADBE) can safely reduce pigment-producing cells in large congenital moles before they are surgically removed. Thirty adults with these birthmarks will apply the cream or a placebo for several weeks before their planned excision. The goal is to see if the treatment lowers the number of melanocytes and lightens the mole, potentially making surgery easier or less extensive.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Squaric acid dibutyl ester (SADBE) applied as a topical solution
- What this could lead to
- If it works, this could point toward a non-surgical way to lighten or shrink congenital moles before removal, potentially reducing scarring or need for extensive surgery.
- What could go wrong
- This is a very early (Phase 1) trial with only 30 people, so it may not show clear benefit. The treatment is topical but could cause skin irritation or allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL MELANOCYTIC NEVUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.